losartan has been researched along with Pheochromocytoma in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Pheochromocytoma: A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study using a rat pheochromocytoma cell line, which expresses AT2 exclusively, we found that angiotensin II inhibits phosphotyrosine phosphatase activity in vivo as measured by the inhibition of hydrolysis of [32P]-phosphate from the 32P-labeled synthetic peptide substrate, Raytide." | 7.69 | Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2. ( Bardhan, S; Inagami, T; Kambayashi, Y; Shirai, H; Takahasi, K, 1994) |
| " In the present study using a rat pheochromocytoma cell line, which expresses AT2 exclusively, we found that angiotensin II inhibits phosphotyrosine phosphatase activity in vivo as measured by the inhibition of hydrolysis of [32P]-phosphate from the 32P-labeled synthetic peptide substrate, Raytide." | 3.69 | Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2. ( Bardhan, S; Inagami, T; Kambayashi, Y; Shirai, H; Takahasi, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Novosel, A | 1 |
| Heger, A | 1 |
| Lohse, P | 1 |
| Schmidt, H | 1 |
| Takahasi, K | 1 |
| Bardhan, S | 1 |
| Kambayashi, Y | 1 |
| Shirai, H | 1 |
| Inagami, T | 1 |
| Speth, RC | 1 |
| Kim, KH | 1 |
3 other studies available for losartan and Pheochromocytoma
| Article | Year |
|---|---|
Multiple pheochromocytomas and paragangliomas in a young patient carrying a SDHD gene mutation.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Angiotensin II Type 1 Recep | 2004 |
Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2.
Topics: Adrenal Gland Neoplasms; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compoun | 1994 |
Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II.
Topics: Adrenal Gland Neoplasms; Angiotensin II; Animals; Binding, Competitive; Cell Membrane; Guanosine 5'- | 1990 |